501 episodes

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.

Diabetes Connections with Stacey Simms Type 1 Diabetes Stacey Simms

    • Health & Fitness
    • 4.7 • 169 Ratings

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.

    In the News... Insulin copay cap revived? G7 timeline pushed back, once weekly basal insulin and more!

    In the News... Insulin copay cap revived? G7 timeline pushed back, once weekly basal insulin and more!

    Get caught up on the news and headlines around the diabetes community! The top stories in the last seven days: Senate Republicans nixed an insulin copay cap, but Democrats say they will revisit this issue in a few weeks, Dexcom pushed back their G7 timeline in the USA after the FDA asks for changes, once weekly basal insulin moves forward in trials. Plus, Beyond Type 1 is back in the NYC Marathon and much more!
    Learn more about the T1D Exchange: https://t1dexchange.org/stacey/
    Check out Stacey's book: The World's Worst Diabetes Mom!
    Join the Diabetes Connections Facebook Group!
    Sign up for our newsletter here
    -----
    Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
    -----
    Episode Transcription Below (or coming soon!)
    Please visit our Sponsors & Partners - they help make the show possible!
    *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*  
    Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
    XX
    In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
    https://t1dexchange.org/stacey/
    XX
    The copay cap on insulin may come back before the Senate in a few weeks. Senate Majority Leader Charles Schumer say he’ll bring tht issue back up.. after Republicans blocked it in a sweeping climate, inflation and health care package passed by the Senate on Monday. Speaking on MSNBC’s “The Rachel Maddow Show.” Schumer said, “We’re going to come back and make them vote on that again.” Seven Republicans still voted with all 50 Democrats, three short of the 60 votes needed, and it is possible more Republicans would support it if it came up as a standalone measure. It’s not clear if this would again be a copay cap or in fact a cap on the actual price of insulin for all, including the uninsured.
    https://thehill.com/policy/healthcare/3594003-schumer-senate-will-vote-again-on-35-insulin-cap-after-gop-blocked-it/
    XX
    Dexcom is pushing back the timeline for a U.S. launch the G7. That’s after the FDA raised questions about the device’s software during a review. This has something to do with how the G7 and it’s smartphone apps deliver alarms to users. Looks like maybe a limited release in the 4th quarter of this year and full rollout in 2023 if there aren’t any other hiccups. As you likely know, the G7 is nearly 60-percent smaller than the G6, it’s transmitter and sensor all in one and has a much shorter warmup period. It’s been approved in Europe since March.
    https://www.fiercebiotech.com/medtech/dexcom-resubmit-g7-glucose-monitor-software-fda-review-pushing-back-us-launch
    XX
    One type of once-a-week basal insulin gets the go ahead to move forward with clinical trials in the US. Gan & Lee Pharmaceuticals says it’s investigation drug called GZR4 is more stable with less day to day variation than once a day basal insulin. There are a few of these weekly insulins in trials, none yet approved. Gan & Lee is also doing trials of the drug in China where they are already a big player in the insulin market.
    https://www.ganlee.com/detail/668.html
    XX
    XX
    Good news for Senseonics, makers of the Eversense implantable CGM. Shares were up on second quarter earnings and future expectations. I don’t generally report on stock market moves of diabetes companies, but the past few years have been a bit iffy for Senseonics and there was speculation on whether this CGM option might not be available in the US. They partnered with Ascensia Diabetes Care and got the six month approval for Eversense earlier this year.
    https://www.massdevice.com/senseonics-stock-q2-2022/
    XX
    A new call for comments to the FDA but the deadline is TODAY august 15 at midnight eastern time. I’m going to read directly fr

    • 7 min
    Episode 500! Behind the Scenes & What's Next, with WMTW's Cristina Frank

    Episode 500! Behind the Scenes & What's Next, with WMTW's Cristina Frank

    I started Diabetes Connections back in the summer of 2015. I'm not sure I had a number of episodes in mind when I kicked off the show, I just knew I wanted to make a podcast for and about the diabetes community. Thanks for tuning in all this time! For episode 500, I've turned hosting duties over to Cristina Frank, a TV news anchor who lives with type 1.
    We talk about how the episodes come together, what's worked (and what hasn't) and what I might add to the show going forward. We also think about how the community has changed and why the highest praise I could take for this show is that it's authentic. Thanks, all!!  -Stacey
    Check out Stacey's book: The World's Worst Diabetes Mom!
    Join the Diabetes Connections Facebook Group!
    Sign up for our newsletter here
    -----
    Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
    -----
    Episode Transcription Below (or coming soon!)
    Please visit our Sponsors & Partners - they help make the show possible!
    *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

    • 39 min
    50 Years with T1D, But Another Condition Changed Jeff's Life

    50 Years with T1D, But Another Condition Changed Jeff's Life

    Jeff Ryan has lived with type 1 for more than 50 years. But he also has what’s called an essential tremor. Part of the treatment for that included using powerful magnets, which made thinking about diabetes tech.. a little different for Jeff. He talks about being diagnosed as a toddler in 1971, and how treatment for both his tremor and his type 1 have changed.. as well as the power of community for both conditions.
    He recently got his 50 year Joslin Medal and shares how a photo of him in front of a Christmas tree in 1971 played a role. That photo was a bit of a mystery to Jeff for a long time, since he was diagnosed in October.
    2001 story about Jeff's brain surgery: https://www.webmd.com/brain/news/20010822/pacemaker-for-brain-effectively-stops-tremors
    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
    Check out Stacey's book: The World's Worst Diabetes Mom!
    Join the Diabetes Connections Facebook Group!
    Sign up for our newsletter here
    -----
    Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
    -----
    Episode Transcription Below (or coming soon!)
    Please visit our Sponsors & Partners - they help make the show possible!
    *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

    • 40 min
    In the News.. Restoring insulin production, Tandem acquires Capillary Biomedical,

    In the News.. Restoring insulin production, Tandem acquires Capillary Biomedical,

    It's In the News! The tops diabetes stories this week include: Australian scientists say they have a new way to restore insulin production using an existing and approved drug, Tandem rolls out bolus by phone for wider release and acquires Capillary Biomedical, an infusion set maker. Dexcom adds Spanish as a language option for the G6, a necklace is said to be able to monitor glucose levels and Netflix's Purple Hearts focuses on type 1 medical costs as a plot point.
    Learn more about the T1D Exchange: https://t1dexchange.org/stacey/
    Check out Stacey's book: The World's Worst Diabetes Mom!
    Join the Diabetes Connections Facebook Group!
    Sign up for our newsletter here
    -----
    Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
    -----
    Episode Transcription Below (or coming soon!)
    Please visit our Sponsors & Partners - they help make the show possible!
    *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*  
    Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
    XX
    In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
    https://t1dexchange.org/stacey/
    XX
    Australian scientists say they have a new way to restore insulin
    production in pancreatic cells, using a drug that’s already approved for use in humans. In lab experiments on pancreatic stem cells from donors with type 1 diabetes, the team was able to activate them to begin expressing insulin by exposing them to a drug compound known as GSK126. These cells don’t normally produce insulin, but the drug let them functionally step into the shoes of the beta cells that had stopped working. In principle, a single course of this kind of drug over a few days could replace the need for regular insulin shots in diabetics.

    The new treatment would work much faster, within a matter of days, and without the need for surgery. But perhaps the biggest advantage is that GSK126 is already approved by the US FDA and elsewhere in the world as a treatment for cancer. Its safety profile is already being assessed in clinical trials, which could reduce hurdles down the road for its use against diabetes.
    That said, the scientists caution that it is still very early days. These experiments were conducted on cells in culture – not even in animals yet – so there’s still plenty of work to do. Nevertheless, it remains an intriguing new possible tool.

    https://newatlas.com/medical/diabetes-breakthrough-insulin-production-existing-drug/
     
    XX
    Couple of big announcements from Tandem Diabetes this week. They’ve widened the roll out of their Mobile Bolus feature, now open to all customers with in-warranty tslim x2 pumps and compatible smart phones. Approved earlier this year, it has been available for a few weeks to a small group of users.
    https://www.tandemdiabetes.com/products/software-apps/tconnect-mobile
    XX
    Tandem also announced it acquired infusion set developer Capillary Biomedical, an infusion set maker. To quote the press release: Capillary Biomedical’s unique extended wear infusion set technology is currently in development and not commercially available. The company designed its SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability. Capillary Biomedical received FDA investigational device exemption for the platform in January of this year.
    https://www.drugdeliverybusiness.com/tandem-diabetes-acquires-capillary-biomedical-infusion/
    XX
    Dexcom is launching their G6 mobile app in Spanish. It is estimated that 11.8% of U.S. Latino adults have diagnosed diabetes. Dexcom says, “
    “Launching the Dexcom G6 app in Spanish is a positive step toward improving health equity fo

    • 6 min
    "Choose to do Difficult Things" - T1D Ultra-Athlete Sebastien Sasseville

    "Choose to do Difficult Things" - T1D Ultra-Athlete Sebastien Sasseville

    Sebastien Sasseville recently completed The Race Across America, a grueling 3-thousand miles coast to coast cycling event that riders must complete in only 12 days. That means pushing through not just diabetes, Sasseville lives with type 1, but also eating on the bike and sleeping just a few hours at a time.
    Sasseville has been an ultra athlete for two decades now. We get more details about this race, why he wanted to do it and how he managed type 1 throughout.
    More on Sassville here: https://sebinspire.com/en/
    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
    Check out Stacey's book: The World's Worst Diabetes Mom!
    Join the Diabetes Connections Facebook Group!
    Sign up for our newsletter here
    -----
    Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
    -----
    Episode Transcription Below (or coming soon!)
    Please visit our Sponsors & Partners - they help make the show possible!
    *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

    • 42 min
    In the News... Insulin coverage changes, CGM use in older people, another company joins islet cell research and more!

    In the News... Insulin coverage changes, CGM use in older people, another company joins islet cell research and more!

    Top stories In the News this week, United Healthcare announces changes to how they cover insulin for some, a new study looks at CGM use in people with type 2 over the age of 65, another company begins islet cell clinical trials, a new tool to treat diabetic neuropathy pain, gestational diabetes is on the rise, and more.
    Learn more about the T1D Exchange: https://t1dexchange.org/stacey/
    Check out Stacey's book: The World's Worst Diabetes Mom!
    Join the Diabetes Connections Facebook Group!
    Sign up for our newsletter here
    -----
    Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
    -----
    Episode Transcription Below (or coming soon!)
    Please visit our Sponsors & Partners - they help make the show possible!
    *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
    XX
    In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
    https://t1dexchange.org/stacey/
    XX
    Our top story.. United Healthcare says it will have no “out of pocket” expenses for insulin starting January first. It’s doing the same for other critical drugs like glucagon, epinephrine and albuterol. Looking into this a bit more, though, it’s not the boon it first seems. This only covers certain eligible patients. Stat news says about a quarter of United Healthcare’s patients will qualify but I saw a few commentators say it could actually be less than 5-percent. UnitedHealth Group shared that it earned $5.1 billion in profit for the second quarter of 2022.
    https://kstp.com/kstp-news/top-news/united-healthcare-says-no-out-of-pocket-expenses-for-insulin/
    XX
    Not too surprising but a good study about people with type 2 using CGMs. This was for people using basal insulin only and over 65 years old. They found when given a CGM, their A1Cs went down an average of 1 full point with fewer lows. These are the kinds of studies that may seem obvious to us but that are needed to show insurers they need to cover.
    https://www.liebertpub.com/doi/10.1089/dia.2021.0494
    XX
    New device approved to treat pain associated with diabetic peripheral neuropathy. The DyAnsys’ First Relief system is set behind the ear – its an adhesive, nothing surgical. It features three small, acupuncturelike needles that reach through the skin behind the ear to access the nervous system. Once in place, the device continuously emits low-level electrical pulses over the course of several days at a time; the FDA cleared the system for repeated treatments spanning up to eight weeks.
    https://www.fiercebiotech.com/medtech/fda-clears-wearable-neurostimulator-dyansys-treat-pain-diabetic-nerve-damage
    XX
    Another company having success with islet cell transplants. ProtoKinetix announced they’re completely safety objectives and will start phase 1 clinical trials of their molecule PKX-001. Not much to report here yet, but I didn’t want to news of the Vertex/Viactye merger to over shadow that there are other efforts going on here.
    https://www.businesswire.com/news/home/20220720005086/en/ProtoKinetix-Successfully-Completes-Phase-1-Clinical-Trials-for-the-Treatment-of-Type-1-Diabetes-in-Islet-Cell-Transplants
    XX
    Roche and Insulet settle their lawsuit.. this was a patent issue and both companies were suing each other. Insulet will give Roche 20-million dollars and Roche has agreed not to sue Insulet for five years. This was set to go to trial next week.
    https://seekingalpha.com/news/3855728-insulet-to-pay-20m-to-settle-patent-lawsuit
    XX
    Gestational diabetes is on the rise, climbing 30% between 2016 and 2020, according to a new study by the Centers for Disease Control and Prevention.The CDC analysis showed that cases inc

    • 4 min

Customer Reviews

4.7 out of 5
169 Ratings

169 Ratings

Mcshanehenry ,

I learn so much!

Love all the updates about the diabetes world!

GoletaMom ,

Great content!

I love the range of information Stacy shares and the variety of quests. She produces a very professional podcast on diabetes!

Reymaestro ,

An essential for anyone affected by T1D

My son was diagnosed in the middle of the pandemic, resources and connections in person were limited to none. This podcast was an incredible resource in figuring out his care. We decided to go for Tandem’s brand new CIQ at 3 months after diagnosis on 2021. His A1Cs have been in the 5s ever since. I really thank the podcast for helping us make the best decision possible for our son. I love staying on top of what’s new with TD1 technology and I will forever be grateful. Thank you Stacy!!!!

Top Podcasts In Health & Fitness

Scicomm Media
Jay Shetty
Aubrey Gordon & Michael Hobbes
Lewis Howes
Rob Dial and Kast Media
Sal Di Stefano, Adam Schafer, Justin Andrews, Doug Egge

You Might Also Like

Scott Benner
FTF Warrior
Katie Roseborough
Cyrus Khambatta, PhD & Robby Barbaro, MPH (both living with type 1 diabetes
Colleen Mitchell
Amber Clour